Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Indian Journal of Gastroenterology

Volumn 34, Issue 4, 2015, Pages 286-291

  Goyal, Sundeep Kumar ^a   Dixit, Vinod Kumar ^a   Shukla, Suneet Kumar ^a   Ghosh, Jayant ^a   Behera, Manas ^a   Tripathi, Manish ^a   Gupta, Neha ^a   Ranjan, Arttrika ^a   Jain, Ashok Kumar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Antiviral; Chronic hepatitis B; Hepatitis B Virus; Hepatocellular carcinoma; Liver Cirrhosis; Liver decompensation; Liver fibrosis; Ultrasonography

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TENOFOVIR; GUANINE;

ADULT; ARTICLE; ASCITES; BLEEDING; BRAIN DISEASE; CHILD PUGH SCORE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; ECHOGRAPHY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HOSPITALIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; RECURRENCE RISK; RETROSPECTIVE STUDY; SEROLOGY; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; MIDDLE AGED; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TENOFOVIR; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942984773     PISSN: 02548860     EISSN: 09750711     Source Type: Journal    
DOI: 10.1007/s12664-015-0576-1     Document Type: Article

References (29)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.
2. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–92.
3. Datta S. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virol J. 2008;5:156.
4. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49 Suppl:S45–S55.
5. Wu GY, Chen HS. Novel approaches towards conquering hepatitis B infection. World J Gastroenterol. 2007;13:830–6.
6. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.
7. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.
8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.
9. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.
10. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–93.
11. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.
12. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003;38:1419–27.
13. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349–60.
14. Lim SG, Aung MO, Mak B, et al. Clinical outcomes of lamivudine-adefovir therapy in chronic hepatitis B cirrhosis. J Clin Gastroenterol. 2011;45:818–23.
15. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176–82.
16. Liaw YS, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.
17. Kao JTPC, Lai HC, Chuang PH, et al. Efficacy of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis. J Gastroenterol Hepatol. 2009;24:A202.
18. Liaw YS, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: randomized, open label study. Hepatology. 2011;54:91–100.
19. Pellicelli AM, Barbarini G, Romano M, et al. Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for OLT: viral and biochemical outcomes at one year. Hepatology. 2009;50:514A.
20. Koklu S, Tuna Y, Gulsen MT, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11:88–94.
21. Srivastava M, Rungta S, Dixit VK, Shukla SK, Singh TB, Jain AK. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antiviral Res. 2013;100:300–5.
22. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.
23. Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360–8.
24. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–14.
25. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.
26. Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transplant. 2008;14 Suppl 2:S1–7.
27. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001;34:411–6.
28. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348–56.
29. Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012;35:674–89.